RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has successfully completed its first-in-man Phase I clinical safety study with the novel antibiotic drug candidate PMX-30063. PMX-30063 is the first and only small molecule mimetic of host defense proteins in clinical development, with a novel mechanism of action distinct from other antibiotic drugs, that is believed to work in such a way that makes bacterial resistance unlikely to develop. The data from the study demonstrate that safe and well-tolerated single doses were achieved, at levels suggesting and a beneficial therapeutic index may be possible. Further clinical development will continue for the initial indication for this drug as a treatment for pan-Staphylococcal infections.
